Cited 70 times in
TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 손주혁 | - |
dc.date.accessioned | 2021-09-29T02:35:01Z | - |
dc.date.available | 2021-09-29T02:35:01Z | - |
dc.date.issued | 2020-04 | - |
dc.identifier.issn | 1479-6694 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/185005 | - |
dc.description.abstract | Patients with HR+/HER2- metastatic breast cancer (MBC) whose cancers have progressed despite conventional therapies represent an unmet clinical need. Trop-2, a transmembrane calcium signal transducer, is highly expressed in MBC and plays a role in tumor growth and progression. Sacituzumab govitecan (SG) is a novel antibody-drug conjugate comprising an Trop-2 antibody coupled to SN-38, the active metabolite of irinotecan, via a unique hydrolyzable linker. SG has demonstrated promising activity in a Phase I/II IMMU-132-01 basket study in heavily pretreated solid tumors, including HR+/HER2- MBC. We describe the registrational Phase III TROPiCS-02 study (NCT03901339), evaluating SG versus treatment of physician's choice in HR+/HER2- MBC. Trial registration number: NCT03901339. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Future Medicine Ltd. | - |
dc.relation.isPartOf | FUTURE ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized / administration & dosage | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized / adverse effects | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized / therapeutic use* | - |
dc.subject.MESH | Antigens, Neoplasm | - |
dc.subject.MESH | Antineoplastic Agents, Immunological / administration & dosage | - |
dc.subject.MESH | Antineoplastic Agents, Immunological / adverse effects | - |
dc.subject.MESH | Antineoplastic Agents, Immunological / therapeutic use* | - |
dc.subject.MESH | Biomarkers, Tumor | - |
dc.subject.MESH | Breast Neoplasms / drug therapy* | - |
dc.subject.MESH | Breast Neoplasms / etiology | - |
dc.subject.MESH | Breast Neoplasms / metabolism | - |
dc.subject.MESH | Breast Neoplasms / pathology* | - |
dc.subject.MESH | Camptothecin / administration & dosage | - |
dc.subject.MESH | Camptothecin / adverse effects | - |
dc.subject.MESH | Camptothecin / analogs & derivatives* | - |
dc.subject.MESH | Camptothecin / therapeutic use | - |
dc.subject.MESH | Cell Adhesion Molecules / antagonists & inhibitors | - |
dc.subject.MESH | Drug Resistance, Neoplasm | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunoconjugates / administration & dosage | - |
dc.subject.MESH | Immunoconjugates / adverse effects | - |
dc.subject.MESH | Immunoconjugates / therapeutic use* | - |
dc.subject.MESH | Molecular Targeted Therapy | - |
dc.subject.MESH | Neoplasm Metastasis | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Receptor, ErbB-2 / antagonists & inhibitors | - |
dc.subject.MESH | Retreatment | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hope S Rugo | - |
dc.contributor.googleauthor | Aditya Bardia | - |
dc.contributor.googleauthor | Sara M Tolaney | - |
dc.contributor.googleauthor | Carlos Arteaga | - |
dc.contributor.googleauthor | Javier Cortes | - |
dc.contributor.googleauthor | Joohyuk Sohn | - |
dc.contributor.googleauthor | Frederik Marmé | - |
dc.contributor.googleauthor | Quan Hong | - |
dc.contributor.googleauthor | Rosemary J Delaney | - |
dc.contributor.googleauthor | Amir Hafeez | - |
dc.contributor.googleauthor | Fabrice André | - |
dc.contributor.googleauthor | Peter Schmid | - |
dc.identifier.doi | 10.2217/fon-2020-0163 | - |
dc.contributor.localId | A01995 | - |
dc.relation.journalcode | J00914 | - |
dc.identifier.eissn | 1744-8301 | - |
dc.identifier.pmid | 32223649 | - |
dc.subject.keyword | HER2-negative | - |
dc.subject.keyword | HR-positive | - |
dc.subject.keyword | MBC | - |
dc.subject.keyword | SN-38 | - |
dc.subject.keyword | Trop-2 | - |
dc.subject.keyword | antibody–drug conjugate | - |
dc.subject.keyword | metastatic breast cancer | - |
dc.subject.keyword | sacituzumab govitecan | - |
dc.contributor.alternativeName | Sohn, Joo Hyuk | - |
dc.contributor.affiliatedAuthor | 손주혁 | - |
dc.citation.volume | 16 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 705 | - |
dc.citation.endPage | 715 | - |
dc.identifier.bibliographicCitation | FUTURE ONCOLOGY, Vol.16(12) : 705-715, 2020-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.